EA201270423A1 - Ингибиторы протеазы hcv - Google Patents
Ингибиторы протеазы hcvInfo
- Publication number
- EA201270423A1 EA201270423A1 EA201270423A EA201270423A EA201270423A1 EA 201270423 A1 EA201270423 A1 EA 201270423A1 EA 201270423 A EA201270423 A EA 201270423A EA 201270423 A EA201270423 A EA 201270423A EA 201270423 A1 EA201270423 A1 EA 201270423A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- protease inhibitors
- hcv protease
- compounds
- relates
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Настоящее изобретение относится к макроциклическим соединениям, представленным в описании. Указанные соединения могут быть использованы для лечения инфекции вирусом гепатита С.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2009/056937 WO2011034518A1 (en) | 2009-09-15 | 2009-09-15 | Hcv protease inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201270423A1 true EA201270423A1 (ru) | 2012-09-28 |
EA022118B1 EA022118B1 (ru) | 2015-11-30 |
Family
ID=43758907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201270423A EA022118B1 (ru) | 2009-09-15 | 2009-09-15 | Ингибиторы протеазы hcv |
Country Status (21)
Country | Link |
---|---|
US (1) | US8389560B2 (ru) |
EP (1) | EP2477980B1 (ru) |
JP (1) | JP5702388B2 (ru) |
KR (1) | KR101670319B1 (ru) |
AU (1) | AU2009352688B2 (ru) |
CA (1) | CA2774145C (ru) |
CY (1) | CY1118136T1 (ru) |
DK (1) | DK2477980T3 (ru) |
EA (1) | EA022118B1 (ru) |
ES (1) | ES2588204T3 (ru) |
HR (1) | HRP20161025T1 (ru) |
HU (1) | HUE030402T2 (ru) |
LT (1) | LT2477980T (ru) |
NZ (1) | NZ599133A (ru) |
PL (1) | PL2477980T3 (ru) |
PT (1) | PT2477980T (ru) |
SG (1) | SG179566A1 (ru) |
SI (1) | SI2477980T1 (ru) |
SM (1) | SMT201600291B (ru) |
WO (1) | WO2011034518A1 (ru) |
ZA (1) | ZA201202631B (ru) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
WO2010045266A1 (en) * | 2008-10-15 | 2010-04-22 | Intermune, Inc. | Therapeutic antiviral peptides |
WO2011038293A1 (en) * | 2009-09-28 | 2011-03-31 | Intermune, Inc. | Cyclic peptide inhibitors of hepatitis c virus replication |
TW201116540A (en) * | 2009-10-01 | 2011-05-16 | Intermune Inc | Therapeutic antiviral peptides |
US20110178107A1 (en) * | 2010-01-20 | 2011-07-21 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
BR112013016480A2 (pt) | 2010-12-30 | 2016-09-20 | Abbvie Inc | macrocíclo da fenantridina inibadores da protease da serina da hepatite c |
JP2014502620A (ja) | 2010-12-30 | 2014-02-03 | エナンタ ファーマシューティカルズ インコーポレイテッド | 大環状c型肝炎セリンプロテアーゼ阻害剤 |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
CN102911254A (zh) * | 2011-08-02 | 2013-02-06 | 上海唐润医药科技有限公司 | Hcv蛋白酶抑制剂 |
CN107964006A (zh) * | 2012-01-11 | 2018-04-27 | 艾伯维公司 | 用于制备hcv蛋白酶抑制剂的方法 |
JP6333262B2 (ja) * | 2012-09-20 | 2018-05-30 | ユー・ディー・シー アイルランド リミテッド | 電子用途のためのアザジベンゾフラン |
JP2015533124A (ja) | 2012-10-08 | 2015-11-19 | アッヴィ・インコーポレイテッド | Hcvプロテアーゼ阻害剤を作製するのに有用な化合物 |
JP6154474B2 (ja) | 2012-10-19 | 2017-06-28 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9580463B2 (en) | 2013-03-07 | 2017-02-28 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN104557954A (zh) * | 2013-10-16 | 2015-04-29 | 上海唐润医药科技有限公司 | 抗hcv的大环化合物 |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
CN104447952A (zh) * | 2014-12-11 | 2015-03-25 | 上海唐润医药科技有限公司 | 丙肝病毒蛋白酶抑制剂及其合成方法 |
CN108727417B (zh) * | 2015-02-05 | 2021-10-08 | 爱博新药研发(上海)有限公司 | 多环化合物钠盐及其多晶型、制备方法及应用 |
JP2019521995A (ja) * | 2016-06-22 | 2019-08-08 | 出光興産株式会社 | 有機発光ダイオード用の特定位置が置換されたベンゾフロ−又はベンゾチエノキノリン |
US10004719B1 (en) | 2017-05-30 | 2018-06-26 | Taigen Biotechnology Co., Ltd. | Solid dispersion formulation |
CN110958880B (zh) * | 2017-05-30 | 2023-08-08 | 东莞东阳光太景医药研发有限责任公司 | 固体分散制剂 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4555508A (en) * | 1984-03-02 | 1985-11-26 | Usv Pharmaceutical Corp. | Antihypertensive spiro-cyclic compounds |
CA2254122A1 (en) | 1996-05-10 | 1997-11-20 | Schering Corporation | Synthetic inhibitors of hepatitis c virus ns3 protease |
US5990276A (en) | 1996-05-10 | 1999-11-23 | Schering Corporation | Synthetic inhibitors of hepatitis C virus NS3 protease |
US5876984A (en) * | 1996-09-25 | 1999-03-02 | Shionogi & Co., Ltd | Sequiterpene derivatives having antiviral activity |
ZA979327B (en) | 1996-10-18 | 1998-05-11 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease. |
GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
ATE283865T1 (de) | 1997-08-11 | 2004-12-15 | Boehringer Ingelheim Ca Ltd | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c |
JP4690545B2 (ja) | 1998-03-31 | 2011-06-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子 |
US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
US20030073618A1 (en) | 2001-02-08 | 2003-04-17 | Kozhemyakin Leonid A. | Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof |
US20020182647A1 (en) | 2001-04-30 | 2002-12-05 | Emmert-Buck Michael R. | Histoscreen method |
NZ530000A (en) * | 2001-07-11 | 2007-03-30 | Vertex Pharma | Peptidomimetic bridged bicyclic serine protease inhibitors |
US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
WO2003062228A1 (en) * | 2002-01-23 | 2003-07-31 | Schering Corporation | Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection |
US7119072B2 (en) * | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
US7273885B2 (en) | 2002-04-11 | 2007-09-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
ATE413411T1 (de) * | 2002-05-20 | 2008-11-15 | Bristol Myers Squibb Co | Substituierte cycloalkyl p1' hepatitis c virus inhibitoren |
US7601367B2 (en) | 2002-05-28 | 2009-10-13 | Mirus Bio Llc | Compositions and processes using siRNA, amphipathic compounds and polycations |
WO2004041818A1 (en) | 2002-11-01 | 2004-05-21 | Abbott Laboratories | Anti-infective agents |
JP2007524576A (ja) | 2003-02-07 | 2007-08-30 | エナンタ ファーマシューティカルズ インコーポレイテッド | 大環状のc型肝炎セリンプロテアーゼ阻害剤 |
EP1613620A1 (en) | 2003-04-11 | 2006-01-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
EP1636208B1 (en) | 2003-04-11 | 2012-02-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
ES2386161T3 (es) | 2003-04-16 | 2012-08-10 | Bristol-Myers Squibb Company | Proceso para separar una mezcla de enantiómeros de éster alquílico usando una enzima |
US7176208B2 (en) * | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
KR101137572B1 (ko) | 2003-06-11 | 2012-05-30 | 이데라 파마슈티칼즈, 인코포레이티드 | 안정화된 면역조절 올리고뉴클레오티드 |
AU2004257288A1 (en) | 2003-07-18 | 2005-01-27 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
JP4685775B2 (ja) | 2003-09-18 | 2011-05-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、とりわけhcvns3−ns4aプロテアーゼの阻害剤 |
BRPI0414571A (pt) | 2003-09-22 | 2006-11-07 | Boehringer Ingelheim Int | peptìdeos macrocìclicos ativos contra o vìrus da hepatite c |
BRPI0414814A (pt) * | 2003-09-26 | 2006-11-14 | Schering Corp | inibidores macrocìclicos de protease de serina ns3 de vìrus de hepatite c |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
US7253160B2 (en) * | 2003-11-20 | 2007-08-07 | Schering Corporation | Depeptidized inhibitors of hepatitis C virus NS3 protease |
EP1742913A1 (en) * | 2003-12-11 | 2007-01-17 | Schering Corporation | Inhibitors of hepatitis c virus ns3/ns4a serine protease |
CA2549851C (en) | 2004-01-21 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
JP2008513454A (ja) * | 2004-09-17 | 2008-05-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 大環状hcvプロテアーゼインヒビターの調製方法 |
US20070207949A1 (en) * | 2005-06-02 | 2007-09-06 | Anima Ghosal | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor |
US20070237818A1 (en) * | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
CA2611145A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation useful for treating disorders associated with hepatitis c virus |
PE20080992A1 (es) * | 2006-06-26 | 2008-08-06 | Enanta Pharm Inc | Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c |
WO2008022006A2 (en) * | 2006-08-11 | 2008-02-21 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis c virus protease inhibitors |
US7605126B2 (en) * | 2006-08-11 | 2009-10-20 | Enanta Pharmaceuticals, Inc. | Acylaminoheteroaryl hepatitis C virus protease inhibitors |
US20080267917A1 (en) * | 2007-04-26 | 2008-10-30 | Deqiang Niu | N-functionalized amides as hepatitis c serine protease inhibitors |
US20080274080A1 (en) * | 2007-04-26 | 2008-11-06 | Yat Sun Or | Aza-peptide macrocyclic hepatitis c serine protease inhibitors |
US20090005387A1 (en) * | 2007-06-26 | 2009-01-01 | Deqiang Niu | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors |
US20090111757A1 (en) * | 2007-10-25 | 2009-04-30 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
-
2009
- 2009-09-15 NZ NZ599133A patent/NZ599133A/xx not_active IP Right Cessation
- 2009-09-15 US US12/559,818 patent/US8389560B2/en active Active
- 2009-09-15 PT PT98496060T patent/PT2477980T/pt unknown
- 2009-09-15 WO PCT/US2009/056937 patent/WO2011034518A1/en active Application Filing
- 2009-09-15 JP JP2012529723A patent/JP5702388B2/ja not_active Expired - Fee Related
- 2009-09-15 EP EP09849606.0A patent/EP2477980B1/en active Active
- 2009-09-15 EA EA201270423A patent/EA022118B1/ru unknown
- 2009-09-15 CA CA2774145A patent/CA2774145C/en active Active
- 2009-09-15 HU HUE09849606A patent/HUE030402T2/en unknown
- 2009-09-15 SG SG2012018412A patent/SG179566A1/en unknown
- 2009-09-15 ES ES09849606.0T patent/ES2588204T3/es active Active
- 2009-09-15 SI SI200931505A patent/SI2477980T1/sl unknown
- 2009-09-15 AU AU2009352688A patent/AU2009352688B2/en not_active Ceased
- 2009-09-15 PL PL09849606T patent/PL2477980T3/pl unknown
- 2009-09-15 LT LTEP09849606.0T patent/LT2477980T/lt unknown
- 2009-09-15 KR KR1020127009259A patent/KR101670319B1/ko active IP Right Grant
- 2009-09-15 DK DK09849606.0T patent/DK2477980T3/en active
-
2012
- 2012-04-12 ZA ZA2012/02631A patent/ZA201202631B/en unknown
-
2016
- 2016-08-16 HR HRP20161025TT patent/HRP20161025T1/hr unknown
- 2016-08-29 SM SM201600291T patent/SMT201600291B/it unknown
- 2016-08-31 CY CY20161100856T patent/CY1118136T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EA022118B1 (ru) | 2015-11-30 |
KR101670319B1 (ko) | 2016-10-28 |
SG179566A1 (en) | 2012-05-30 |
JP2013504616A (ja) | 2013-02-07 |
AU2009352688B2 (en) | 2014-04-17 |
JP5702388B2 (ja) | 2015-04-15 |
SI2477980T1 (sl) | 2017-01-31 |
CY1118136T1 (el) | 2017-06-28 |
PT2477980T (pt) | 2016-08-31 |
SMT201600291B (it) | 2016-11-10 |
DK2477980T3 (en) | 2016-09-12 |
HRP20161025T1 (hr) | 2016-11-04 |
EP2477980A4 (en) | 2013-05-01 |
HUE030402T2 (en) | 2017-05-29 |
ZA201202631B (en) | 2012-12-27 |
WO2011034518A1 (en) | 2011-03-24 |
US20110065737A1 (en) | 2011-03-17 |
US8389560B2 (en) | 2013-03-05 |
CA2774145C (en) | 2015-10-27 |
EP2477980A1 (en) | 2012-07-25 |
CA2774145A1 (en) | 2011-03-24 |
LT2477980T (lt) | 2016-09-26 |
AU2009352688A1 (en) | 2012-04-26 |
EP2477980B1 (en) | 2016-06-08 |
ES2588204T3 (es) | 2016-10-31 |
PL2477980T3 (pl) | 2017-02-28 |
KR20120110091A (ko) | 2012-10-09 |
NZ599133A (en) | 2013-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201270423A1 (ru) | Ингибиторы протеазы hcv | |
EA201071315A1 (ru) | Ингибиторы протеазы вируса гепатита с | |
EA200901101A1 (ru) | Макроциклические соединения в качестве ингибиторов протеазы ns3 вгс | |
EA201390190A1 (ru) | Ингибиторы вируса гепатита с | |
EA201270616A1 (ru) | Ингибиторы вируса гепатита с | |
TN2011000014A1 (en) | Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors | |
EA200970805A1 (ru) | Ингибиторы серинпротеаз для лечения hcv инфекций | |
TW200833678A (en) | HCV protease inhibitorscross reference | |
WO2011049987A3 (en) | Azaindazoles to treat flaviviridae virus infection | |
EA201190224A1 (ru) | Ингибиторы гепатита c, содержащие конденсированные кольца | |
WO2012083048A3 (en) | Anti-viral compounds | |
MX2011006631A (es) | Inhibidores de proteasa ns3 del virus hcv. | |
WO2012083053A3 (en) | Anti-viral compounds | |
EA201391152A1 (ru) | Ингибиторы вируса гепатита с | |
EA201590384A1 (ru) | 6-аминокислота-гетероарилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в | |
EA201270622A1 (ru) | Ингибиторы вируса гепатита с | |
CO6190510A2 (es) | Inhibidores del virus de la hepatitis c | |
CL2012002489A1 (es) | Compuestos derivados de sililo nafto-imidazol; composición farmacéutica; y su uso para prevenir o tratar una infección por el virus de la hepatitis c. | |
CL2012000919A1 (es) | Composicion que comprende un compuesto derivado de metoxicarbonil-amino-metilbutanoil-pirrolidinil-imidazol de formula i, inhibidor especifico de ns5a de hcv, y un compuesto derivado de oxo-pirrolidin-quinoleina de formula ii, inhibidor de proteasa ns3 de hcv; y uso en el tratamiento de la hepatitis c. | |
SV2009003239A (es) | Inhibidores de la proteasa ns3 del hcv. | |
WO2013074386A3 (en) | Hcv ns3 protease inhibitors | |
WO2008057995A3 (en) | Hcv protease inhibitors | |
EA201370017A1 (ru) | Ингибиторы вируса гепатита с | |
WO2012083061A3 (en) | Anti-viral compounds | |
EA201391637A1 (ru) | Ингибиторы вируса гепатита c |